Early Phase Research - Autoimmune
Case Study: Delivering an Early-Phase Autoimmune Trial Across Regions
|
has not third author: true, (SizeLimitingPyMap: {main={}, second={}, third={}})
Life-changing therapies
without a lifetime of
development
Precision for Medicine solves the most complex clinical development challenges to bring innovative therapies to patients.
Contact Us
No one who is working to help patients in need should be subjected to unnecessary delays during clinical development and commercialization. Precision’s integrated capabilities, responsive operations and deep scientific expertise are helping life science innovators accelerate research and development while reducing cost and increasing the probability of approval.
Specialized capabilities for every stage of clinical development
Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to increase speed to market. Precision brings a holistic view to your program's unique needs.
-
Discover Explore
Global CRO
ServicesAward-winning CRO with deep oncology and rare disease expertise
-
Discover Explore
Global Laboratory
ServicesExceptional translational and biomarker sciences with global clinical logistics services
-
Discover BiospecimensBiospecimens
-
Discover Diagnostics & CDxDiagnostics & CDx
-
Discover Data IntelligenceData Intelligence
-
Discover CommercializationCommercialization
-
Discover Optimize early phase development
.webp?width=632&height=410&name=image%2037%20(1).webp)
Optimize early phase development
How can you successfully navigate the complexities of early phase development? Integrated clinical and laboratory sciences capabilities are vital. Over 25 years of experience in early oncology development helps anticipate and mitigate a diverse set of risks, including complicated kitting and sample management.
-
Discover Maximize late phase development
.webp?width=632&height=410&name=image%2037%20(2).webp)
Maximize late phase development
Congratulations if you are entering late phase development. Now you’ll need a partner that can recruit patients most likely to respond to treatment, manage complex protocols, anticipate global regulatory requirements, enable manufacturing, support commercial viability and more. Let us drive your innovation to market and empower access for patients.
Trusted partner to leading innovators in oncology and rare disease
Clinical development is growing more complicated. Progress can hinge on the ability to navigate a shifting pathway to approval. Your path may be unique from those who have gone before, but our experience will help inform success. Precision is a leader in oncology and rare disease research. Our deep experience in complex indications accelerates the ability to reach key milestones, drive positive outcomes and most importantly, help patients get access to innovative treatments.
70
of clinical trials are in oncology
2500
clinical trial and lab projects
5
specialty labs in the US and Europe
30
in investments raised for biotech in the last 5 years
Winner of the 2025 Fierce Biotech CRO Award for Innovative Solutions in Drug Development
Precision is dedicated to operational excellence and our collaborative approach to tackling complex challenges in oncology and rare disease research.
This recognition highlights our successful rescue of a high-risk hematology-oncology trial, where we conducted a full operational and data gap analysis, rebuilt sponsor alignment through proactive collaboration, implemented centralized patient-level data monitoring, and developed custom tracking systems to accelerate regulatory and startup activities.
We’re proud to help advance critical therapies and grateful to the sponsors, investigators, and teams who make this work possible.
Deep experience with debilitating disease and unique modalities
Like you, we understand that there’s a patient throughout the development pathway. Supporting our partners to bring innovative treatments to patients is our purpose. Leverage our experience in these therapeutic areas.
Insights for the greater good
We feel privileged to work in an industry that can change lives. When knowledge is shared, it is amplified. Expanding our collective intelligence can bring remedies to market faster.
Case Study: Delivering an Early-Phase Autoimmune Trial Across Regions
Early‑Phase Autoimmune Drug Development: Trial Design, Biomarkers and Statistical Strategies
has not third author: true, (SizeLimitingPyMap: {main={hs_id=213698206365, hs_child_table_id=0, hs_updated_at=1780680681226, hs_published_at=1780680684943, description=Rui F. Duarte‑Lopes is a senior biostatistics leader with over 31 years of international experience across biopharmaceutical, biotechnology, and CRO sectors. He provides strategic statistical oversight, ensuring rigorous, high‑quality, and decision‑focused delivery aligned with sponsor and regulatory expectations. He has more than 12 years of CRO experience supporting Phase I–IV clinical trials and has held roles including Lead Statistician, Project Lead, and Senior Manager. His therapeutic experience includes oncology and autoimmune diseases, notably lupus erythematosus, Crohn's disease and rheumatoid arthritis. Specializing in oncology over the past six years, Rui focuses on advanced solid tumors and early‑phase studies, contributing to study design, interim analyses, and data‑driven decision frameworks., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Rui%20F%20Duarte-Lopes.jpg',altText='Rui F Duarte-Lopes',fileId=213695319705}, lastname=Duarte-Lopes, hs_initial_published_at=1779886328878, hs_created_by_user_id=26433386, hs_created_at=1779886165792, hs_is_edited=false, hs_deleted_at=0, name=Rui F, job=Senior Manager, Biostatistics, slug=rui-f-duarte-lopes, hs_updated_by_user_id=26433386}, second={}, third={}})
Case Study: Advancing IHC Assays from RUO to Clinical Trials and CDx
has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778874, hs_child_table_id=0, hs_updated_at=1765824406763, hs_published_at=1780680684943, description=Kennon Daniels is a scientific and regulatory in vitro diagnostic authority, specializing in the development of US regulatory strategies and FDA marketing submissions for IVD assays and instruments. Her expertise spans all aspects of product development, analytical and clinical trial protocol designs, Q-Submissions, IDEs, de novos, 510(k)s, and pre-market approval platforms., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Kennon%20Daniels.webp',altText='Kennon Daniels',fileId=165893120790}, linkedin=https://www.linkedin.com/in/kennon-daniels-ph-d-84a90b6, hs_name=, hs_path=, lastname=Daniels, PhD, hs_initial_published_at=1775839468505, hs_created_at=1709645745105, hs_is_edited=false, hs_deleted_at=0, name=Kennon, position=Vice President, IVD Regulatory Consulting, job=, slug=kennon-daniels, email=, hs_updated_by_user_id=26433386}, second={hs_id=164426546714, hs_child_table_id=0, hs_updated_at=1778171432595, hs_published_at=1780680684943, description=Angélique Heckmann, PhD is a people‑driven leader who combines scientific expertise and business acumen with a strong foundation in human values. With a background in therapeutic drug development and an MBA‑shaped strategic mindset, she focuses on building meaningful, long‑term relationships with teams, partners, and clients. By bridging science and strategy, she supports informed decision‑making, fosters collaboration, and helps translate innovation into real‑world impact—always guided by a shared purpose: advancing solutions that ultimately improve patients’ lives, avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/angelique-1.png',altText='angelique-1',fileId=194126030110}, lastname=Heckmann, PhD, hs_initial_published_at=1713174153602, hs_created_by_user_id=62155952, hs_created_at=1713172107894, hs_is_edited=false, hs_deleted_at=0, name=Angelique, job=Regional Vice President, Translational Business Solutions, slug=angelique-heckmann, hs_updated_by_user_id=26433386}, third={}})
